The benefit depends on the medicine
Cannabinoid treatment has established uses in specific neurological conditions. Two concrete examples are the THC/CBD medicine Sativex for selected adults with multiple-sclerosis spasticity and purified cannabidiol, Epidyolex, for specified severe epilepsies. These are different medicines with different indications. Their clinical value lies in reducing defined symptoms, rather than delivering a single general effect called improved health.
Sativex: reducing spasticity symptoms
Spain’s AEMPS product information describes Sativex as additional treatment for moderate-to-severe spasticity due to multiple sclerosis when other antispastic medicines have not worked adequately. Continued use depends on a clinically significant response during an initial trial period. The target is symptom improvement: spasticity involves abnormal muscle stiffness and spasms. Reducing that burden does not mean curing multiple sclerosis or repairing every neurological consequence of the disease.
Epidyolex: fewer seizures
EMA authorisation covers add-on Epidyolex with clobazam for Lennox–Gastaut or Dravet syndrome from age two, and add-on treatment for tuberous sclerosis complex from age two. The clinical endpoint is reduction in seizures. In the TSC study summarised by EMA, seizure frequency decreased 49% in the cannabidiol group versus 27% with placebo. That is a meaningful group comparison within a specific treatment setting, rather than a prediction of the result for each patient.
Benefit and adverse effects coexist
Sativex can cause dizziness and has cautions concerning balance and falls. Epidyolex can cause sleepiness, diarrhoea and appetite changes; liver-enzyme elevation is an important monitoring issue. These effects belong to the same pharmacological treatments that provide benefits. Evaluation therefore involves both symptom response and tolerability, not the assumption that plant origin removes the need for clinical follow-up.
Spain’s 2026 preparation pathway
Alongside authorised medicines, Royal Decree 903/2025 and the 2026 National Formulary monograph define a hospital route for standardised cannabis preparations. The oral THC/CBD monograph covers refractory spasticity, severe epilepsy, chemotherapy-related nausea and vomiting, and chronic pain as last-line treatment when authorised industrial medicines do not satisfactorily treat the individual. This broadens the pharmaceutical framework while retaining a condition-specific, professionally supervised approach.
Sources & further reading
General information, not individual legal or medical advice.